Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Buchmann, A; Pirpamer, L; Pinter, D; Voortman, M; Helmlinger, B; Pichler, A; Maceski, AM; Benkert, P; Bachmaier, G; Ropele, S; Reindl, M; Leppert, D; Kuhle, J; Enzinger, C; Khalil, M.
High serum neurofilament light chain levels correlate with brain atrophy and physical disability in multiple sclerosis.
Eur J Neurol. 2023; 30(5):1389-1399
Doi: 10.1111/ene.15742
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Buchmann Arabella
- Khalil Michael
- Co-Autor*innen der Med Uni Graz
- Bachmaier Gerhard
- Enzinger Christian
- Helmlinger Birgit
- Pichler Alexander
- Pinter Daniela Theresia
- Pirpamer Lukas
- Reindl Marco
- Ropele Stefan
- Voortman Margarete Maria
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND PURPOSE: Serum neurofilament light chain (sNfL) is a promising biomarker of neuroaxonal damage in persons with multiple sclerosis (pwMS). In cross-sectional studies, sNfL has been associated with disease activity and brain magnetic resonance imaging (MRI) changes; however, it is still unclear to what extent in particular high sNfL levels impact on subsequent disease evolution. METHODS: sNfL was quantified by an ultrasensitive single molecule array (Simoa) in 199 pwMS (median age = 34.2 years, 64.3% female) and 49 controls. All pwMS underwent 3-T MRI to assess global and compartmental normalized brain volumes, T2-lesion load, and cortical mean thickness. Follow-up data and serum samples were available in 144 pwMS (median follow-up time = 3.8 years). Linear and binary logistic models were used to estimate the independent contribution of sNfL for changes in MRI and Expanded Disability Status Scale (EDSS). Age-corrected sNfL z-scores from a normative database of healthy controls were used for sensitivity analyses. RESULTS: High sNfL levels at baseline were associated with atrophy measures of the whole brain (standardized beta coefficient βj = -0.352, p < 0.001), white matter (βj = -0.229, p = 0.007), thalamus (βj = -0.372, p = 0.004), and putamen (βj = -1.687, p = 0.012). pwMS with high levels of sNfL at baseline and follow-up had a greater risk of EDSS worsening (p = 0.007). CONCLUSIONS: Already single time point elevation of sNfL has a distinct effect on brain volume changes over a short-term period, and repeated high levels of sNfL indicate accumulating physical disability. Serial assessment of sNfL may provide added value in the clinical management of pwMS.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Female - administration & dosage
- Adult - administration & dosage
- Male - administration & dosage
- Multiple Sclerosis - pathology
- Cross-Sectional Studies - administration & dosage
- Intermediate Filaments - administration & dosage
- Brain - diagnostic imaging, pathology
- Central Nervous System Diseases - administration & dosage
- Biomarkers - administration & dosage
- Neurofilament Proteins - administration & dosage
- Atrophy - pathology
- Neurodegenerative Diseases - pathology
- Find related publications in this database (Keywords)
- atrophy
- disability
- multiple sclerosis
- neurodegeneration
- neurofilament